Terms: = Leukemia AND MECOM, MDS1-EVI1, EVI1, 2122, ENSG00000085276, Q03112, PRDM3
473 results:
1. Oncogene
Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
[TBL] [Abstract] [Full Text] [Related]
2. High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia.
Jessop SJ; Fuentos-Bolanos N; Mayoh C; Dolman MEM; Tax G; Wong-Erasmus M; Ajuyah P; Tyrell V; Marshall GM; Ziegler DS; Lau LMS
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2061. PubMed ID: 38662349
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
4. Promoter-centred chromatin interactions associated with evi1 expression in evi1+3q- myeloid leukaemia cells.
Ng HL; Robinson ME; May PC; Innes AJ; Hiemeyer C; Feldhahn N
Br J Haematol; 2024 Mar; 204(3):945-958. PubMed ID: 38296260
[TBL] [Abstract] [Full Text] [Related]
5. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and evi1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
6. [The role of SF3B1 mutations in evi1-rearranged myeloid neoplasms].
Tanaka A
Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
[TBL] [Abstract] [Full Text] [Related]
7. A primary pediatric acute myelomonocytic leukemia with t(3;21)(q26;q22): A case report.
Duan JX; Liu F; Chang L; Che GL; Yang QX; Teng J; Jian H; Liu XJ; Lai SY
Medicine (Baltimore); 2023 Oct; 102(43):e35721. PubMed ID: 37904382
[TBL] [Abstract] [Full Text] [Related]
8. Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD.
Uchiyama T; Kawai T; Nakabayashi K; Nakazawa Y; Goto F; Okamura K; Nishimura T; Kato K; Watanabe N; Miura A; Yasuda T; Ando Y; Minegishi T; Edasawa K; Shimura M; Akiba Y; Sato-Otsubo A; Mizukami T; Kato M; Akashi K; Nunoi H; Onodera M
Mol Ther; 2023 Dec; 31(12):3424-3440. PubMed ID: 37705244
[TBL] [Abstract] [Full Text] [Related]
9. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J; Fiskus WC; Daver N; Wilson NR; Ravandi F; Garcia-Manero G; Kadia T; DiNardo CD; Jabbour E; Burger J; Short NJ; Alvarado Y; Jain N; Masarova L; Issa GC; Qiao W; Khoury JD; Pierce S; Miller D; Sasaki K; Konopleva M; Bhalla KN; Borthakur G; Pemmaraju N
Clin Cancer Res; 2023 Nov; 29(21):4352-4360. PubMed ID: 37585491
[TBL] [Abstract] [Full Text] [Related]
10. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
11. Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute leukemia and Myeloid Disorders with Recurrent Gene Rearrangements.
Li Y; Deng K; Kaner J; Geyer JT; Ouseph M; Fang F; Xu K; Roboz G; Kluk MJ
Pathobiology; 2024; 91(1):76-88. PubMed ID: 37490880
[TBL] [Abstract] [Full Text] [Related]
12. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract] [Full Text] [Related]
13. Identifying prognostic gene panels in acute myeloid leukemia.
Sanchez-Garcia J; Serrano J; Prados de La Torre E; Serrano-López J; Aparicio-Perez C; Barragán E; Montesinos P
Expert Rev Hematol; 2023 Apr; 16(4):277-287. PubMed ID: 36951195
[TBL] [Abstract] [Full Text] [Related]
14. RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification.
Yang Y; Shu Y; Tang Y; Zhao S; Jia Y; Ji J; Ma H; Lin T; Zheng K; Xu H; Wu Y
Cancer Med; 2023 Apr; 12(8):9156-9166. PubMed ID: 36916780
[TBL] [Abstract] [Full Text] [Related]
15. Validation of the prognostic significance of the 2022 European leukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract] [Full Text] [Related]
16. Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group.
Chisholm KM; Smith J; Heerema-McKenney AE; Choi JK; Ries RE; Hirsch BA; Raimondi SC; Wang YC; Dang A; Alonzo TA; Sung L; Aplenc R; Gamis AS; Meshinchi S; Kahwash SB
Pediatr Blood Cancer; 2023 May; 70(5):e30251. PubMed ID: 36789545
[TBL] [Abstract] [Full Text] [Related]
17. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia.
Nabil R; Abdellateif MS; Gamal H; Hassan NM; Badawy RH; Ghareeb M; El Ashry MS
Leuk Res; 2023 Mar; 126():107019. PubMed ID: 36657369
[TBL] [Abstract] [Full Text] [Related]
18. [De novo blast phase of chronic myeloid leukemia with 3q26 abnormality diagnosed by cytogenetic analysis of extramedullary lesion].
Matsunaga T; Naganuma K; Tabayashi T; Kawada T; Sakata N; Takahashi Y; Kimura Y; Anan T; Mitsuhashi T; Kubota Y; Sawada K; Yamashita T; Momose S; Higashi M; Tamaru JI; Kizaki M
Rinsho Ketsueki; 2022; 63(12):1643-1647. PubMed ID: 36653137
[TBL] [Abstract] [Full Text] [Related]
19. A genetic disorder reveals a hematopoietic stem cell regulatory network co-opted in leukemia.
Voit RA; Tao L; Yu F; Cato LD; Cohen B; Fleming TJ; Antoszewski M; Liao X; Fiorini C; Nandakumar SK; Wahlster L; Teichert K; Regev A; Sankaran VG
Nat Immunol; 2023 Jan; 24(1):69-83. PubMed ID: 36522544
[TBL] [Abstract] [Full Text] [Related]
20. The adverse impact of ecotropic viral integration site-1 (evi1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
[TBL] [Abstract] [Full Text] [Related]
[Next]
